Oglu, G. I. M. Et Al. 2011. How is the serum concentration of Lamotrigine in polytherapy patients with epilepsy affected by the L48V genetic polymorphism or by smoking?. 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology , (Stuttgart, Germany), 521.

Oglu, G. I. M., Ozkaynakci, A., GÖREN, M. Z., ÖZKARA, Ç., GÜLHAN, R., & Onat, F., (2011). How is the serum concentration of Lamotrigine in polytherapy patients with epilepsy affected by the L48V genetic polymorphism or by smoking? . 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (pp.521). Stuttgart, Germany

Oglu, Gulcebi Et Al. "How is the serum concentration of Lamotrigine in polytherapy patients with epilepsy affected by the L48V genetic polymorphism or by smoking?," 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Stuttgart, Germany, 2011

Oglu, Gulcebi I. Et Al. "How is the serum concentration of Lamotrigine in polytherapy patients with epilepsy affected by the L48V genetic polymorphism or by smoking?." 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology , Stuttgart, Germany, pp.521, 2011

Oglu, G. I. M. Et Al. (2011) . "How is the serum concentration of Lamotrigine in polytherapy patients with epilepsy affected by the L48V genetic polymorphism or by smoking?." 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology , Stuttgart, Germany, p.521.

@conferencepaper{conferencepaper, author={Gulcebi Idriz M. Oglu Et Al. }, title={How is the serum concentration of Lamotrigine in polytherapy patients with epilepsy affected by the L48V genetic polymorphism or by smoking?}, congress name={12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology}, city={Stuttgart}, country={Germany}, year={2011}, pages={521} }